“…Other indirect findings suggesting the association between M694V and amyloidosis are; (1) homozygous M694V patients had higher disease severity scores (Erdağ et al, 2008;Inal et al, 2009;Pasa et al, 2008;Ureten et al, 2010); (2) the resistance to colchicine treatment was more common among homozygous M694V patients (Soylemezoglu et al, 2010); and (3) the M694V/M694V genotype was the most common cause of phenotype 2 disease. The clinical significance of variants other than M694V, M680I, M694I and V726A which were studied in all investigated studies (Akpolat et al, 2010;Albayrak, 2010;Atagunduz et al, 2004;Cakar et al, 2001;Delibaş et al, 2005;Duşunsel et al, 2008;Erdağ et al, 2008;Ertekin et al, 2005;Inal et al, 2009;Ozalkaya et al, 2011;Koksal et al, 2009;Mimouni et al, 2000;Pasa et al, 2008;Peru et al, 2008;Samli et al, 2006;Sayhan et al, 2000;Shohat et al, 1998;Solak et al, 2008;Soylemezoglu et al, 2010;Turkcapar et al, 2007;Ureten et al, 2010;Yalçinkaya et al, 2000;Yilmaz et al, 2001Yilmaz et al, , 2003Yigit et al, 2008) is still under discussion. In Table 2, there were 19 patients having one of these mutations/variants of whom 12 had only these mutations.…”